SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Drug Delivery: Top Headlines

Grunenthal says anti-crush tech Endo uses for Opana ER helps prevent abuse

iStock/RobertHarris000

25-Aug-2016 - Grunenthal has reiterated the benefits of its anti-crush intac tech after licensee Endo withdrew its request to have Opana ER labelled as “abuse deterrent."

Related news

News in brief

Public Patheon's $2bn warchest may bolster biologics offering, analyst

17-Aug-2016 - Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.

update

US FDA changes policy on switching hard gel capsule suppliers

16-Aug-2016 - Drug manufacturers that change hard gelatin capsule suppliers do not need to seek approval beforehand under a policy introduced by the US FDA this week.

Antibiotic resistance most imminent threat to humanity, says bacteriophage maker

16-Aug-2016 - Phages, peptides and live biotherapeutics could help combat antibiotic-resistant bacteria but don’t expect heavy R&D investment until people start dying from post-operative infection, says EpiBiome.

Alnylam picks Jacobs to help construct $200m RNAi manufacturing plant in MA

08-Aug-2016 - Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.

Acino agrees to sell drug delivery patch business to Luye Pharma for $274m

02-Aug-2016 - Acino has agreed to sell its transdermal delivery patch business Luye Pharma Group in a deal that will include its manufacturing site in Miesbach, Germany.

West: Amgen mAb approval helps validate drug delivery tech

01-Aug-2016 - Regulatory approvals are driving interest in West's Smartdose and Crystal Zenith delivery technologies, the firm says ahead of the launch of a monthly-dose version of Amgen's Repatha.

UK regulators OK two Oxford Biomedica sites for cell therapy processing

01-Aug-2016 - The MHRA has granted Oxford Biomedica permission to develop and manufacture cell therapies at two more sites in the UK.

Drug Delivery: Featured news

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...